VHT vs XLV: Broad Health Care, or the Sector Sleeve?

Overview

VHT and XLV are both large-cap healthcare equity ETFs that track narrow healthcare market segments, but they differ in breadth and beta profile. VHT follows the MSCI US Investable Market Health Care 25/50 Index, capturing mid-cap and larger healthcare stocks across the full investable market spectrum. XLV tracks the Health Care Select Sector Index, which focuses exclusively on healthcare stocks within the S&P 500, making it a large-cap concentrated play. The key distinction: VHT casts a wider net; XLV zooms in on mega-cap and large-cap healthcare leaders.

How they differ

The biggest difference is index construction. XLV holds only S&P 500 healthcare constituents—roughly 60–70 large-cap names in pharmaceuticals, medical devices, biotech, and healthcare services. VHT includes those same mega-caps but also adds mid-cap and smaller healthcare companies from the full MSCI US Investable Market universe, giving it meaningfully broader exposure and a lower reported beta of 0.58 versus 0.52.

Second, yield diverges slightly. XLV distributes at 1.53%, about 30 basis points higher than VHT's 1.23%, likely reflecting the concentration of cash-rich mega-cap pharmaceutical and device giants in the S&P 500 index.

Third, economics favor VHT narrowly. VHT carries an expense ratio of 0.09% to XLV's 0.08%, a 1-basis-point edge, though both are cheap. XLV is far larger, with $44.5B in assets versus VHT's $19.4B, meaning liquidity and tight spreads are better at XLV.

Who each is best for

• VHT: Fits investors seeking broader healthcare exposure across market-cap tiers—those willing to include mid-cap innovators and specialty players alongside blue-chip pharma and devices, and who prefer a defensive beta profile (0.58).

• XLV: Fits investors who want pure large-cap healthcare stability and are comfortable limiting holdings to S&P 500–listed names; suits allocations that prioritize mega-cap dividend-payers and benefit from the higher yield and larger fund size.

Key risks to know

• Index concentration in mega-cap pharma and devices. Both funds lean heavily on a handful of large pharmaceutical companies and device makers; holdings likely overlap significantly. XLV's narrower S&P 500 universe amplifies this risk relative to VHT.

• Healthcare regulatory and patent risk. Drug pricing reform, patent cliff events, and FDA approval volatility affect both portfolios. Healthcare is a politically sensitive sector; changes in administration or reimbursement policy can surprise equity holders.

• Mid-cap beta and smaller-stock volatility in VHT. While VHT's lower reported beta (0.58) suggests lower overall market sensitivity, its inclusion of smaller healthcare names introduces idiosyncratic risk that the S&P 500–only XLV avoids.

• Valuation sensitivity. Healthcare equities, especially large-cap pharma, are often valued on forward earnings and pipeline strength rather than current yields. A rise in discount rates or reduced growth expectations can pressure both funds quickly.

Bottom line

If you want the most complete healthcare market exposure with a lower beta profile and are comfortable holding mid-cap names, VHT's breadth and defensive characteristics stand out. If you prefer concentrated large-cap simplicity with a higher yield and deeper liquidity, XLV's S&P 500 focus and larger asset base may suit you better. Both carry healthcare-sector-specific risks around regulation and valuation; neither is a defensive port in a market downturn. Past performance does not predict future results.